Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report)'s stock price traded up 1.5% on Tuesday . The company traded as high as $2.71 and last traded at $2.66. 144,413 shares were traded during trading, a decline of 5% from the average session volume of 151,846 shares. The stock had previously closed at $2.62.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Immix Biopharma to a "hold" rating in a report on Friday, June 27th. HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Immix Biopharma in a research report on Wednesday, June 4th.
Get Our Latest Research Report on IMMX
Immix Biopharma Stock Performance
The business's fifty day moving average price is $2.26 and its two-hundred day moving average price is $2.00.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Immix Biopharma stock. Jane Street Group LLC acquired a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned 0.06% of Immix Biopharma as of its most recent filing with the Securities and Exchange Commission. 11.26% of the stock is currently owned by institutional investors and hedge funds.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Further Reading
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
